Search results
Added:
5 months ago
Source:
Radcliffe CVRM
Patients with chronic kidney disease (CKD) are particularly vulnerable to complications from influenza. A prespecified subgroup analysis of the DANFLU-2 trial has found that a high-dose inactivated influenza vaccine (HD-IIV) provides a greater relative benefit against severe clinical outcomes compared to a standard-dose vaccine (SD-IIV) in this high-risk population.¹MethodologyDANFLU-2 was a…
View more
Added:
7 months ago
Source:
Radcliffe CVRM
For patients with severe hypertriglyceridemia, monthly treatment with olezarsen significantly reduced triglyceride levels and the incidence of acute pancreatitis compared with placebo, according to findings from two pivotal trials, CORE-TIMI 72a and CORE2-TIMI 72b.¹Olezarsen is an antisense oligonucleotide designed to inhibit the production of apolipoprotein C-III (ApoC-III), a key protein in the…
View more
Added:
7 months ago
Source:
Radcliffe CVRM
A post hoc analysis of the STRIDE trial has found that once-weekly semaglutide 1.0 mg consistently improves functional outcomes in people with early symptomatic peripheral artery disease (PAD) and type 2 diabetes (T2D), irrespective of sex.¹˒²This analysis addresses the need for sex-specific data in PAD, where differences in epidemiology, clinical presentation, and treatment response are…
View more
Added:
9 months ago
Source:
Radcliffe CVRM
While major guidelines recommend intensive blood pressure control, the overall balance of benefits and harms has remained uncertain. A new post-hoc, pooled analysis of six major randomised controlled trials has quantified these trade-offs, finding that intensive treatment provides a net clinical benefit over standard control, despite an increase in adverse events.¹Researchers from the Blood…
View more
Added:
7 months ago
Source:
Radcliffe CVRM
Obesity is a primary risk factor for dyslipidaemia and cardiovascular disease (CVD), but the mechanisms linking weight gain to lipid metabolism are not fully understood. A new study suggests that in a specific genetic form of obesity caused by melanocortin 4 receptor (MC4R) deficiency, individuals may have a more favourable cardiometabolic profile despite their higher body weight.¹This multi-part…
View more
Added:
1 month ago
Source:
Radcliffe CVRM
High-sensitivity C-reactive protein (hsCRP), a marker of inflammation, has a debated role in primary cardiovascular (CV) prevention. A large, population-based study using UK Biobank data has provided further insight into its utility as a clinical biomarker for identifying individuals at residual risk who do not have known atherosclerotic cardiovascular disease (ASCVD).¹MethodologyThis population…
View more
Added:
1 year ago
Source:
Radcliffe CVRM
AUTHOR: Greg GuilloryInterim findings from the Phase 3 ESSENCE trial (NCT04822181) published in the New England Journal of Medicine show that weekly treatment with semaglutide 2.4 mg significantly resolves metabolic dysfunction–associated steatohepatitis (MASH) and reduces liver fibrosis. At 72 weeks, semaglutide induced histological resolution of steatohepatitis in 62.9% of patients compared…
View more
Added:
2 months ago
Source:
Radcliffe CVRM
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are known to reduce major atherosclerotic cardiovascular events, but the full extent of their mechanisms is still being explored. The SEMA-VR CardioLink-15 trial investigated whether semaglutide affects the levels of circulating vascular regenerative (VR) cells, which are involved in vessel repair and may modulate atherothrombotic risk.¹…
View more
Added:
4 months ago
Source:
Radcliffe CVRM
With the rising prevalence of obesity and associated cardiovascular-kidney-metabolic (CKM) syndrome, indications for novel therapies are expanding. A new study has quantified the proportion of US adults who meet the approved indications for three key classes of CKM medications, revealing a substantial number are eligible for treatment.¹MethodologyThis cross-sectional study analysed data from…
View more
Added:
1 year ago
Source:
Radcliffe Cardiology
AUTHOR: Jordan Rance; Special Editor: Greg GuilloryAmerican Heart Association, 18th November 2024 – Plozasiran, an investigational RNA interference (RNAi) therapeutic, has demonstrated significant reductions in triglycerides and acute pancreatitis in patients with Familial Chylomicronemia Syndrome (FCS) in the Phase 3 PALISADE clinical trial (NCT05089084; Arrowhead Pharmeceuticals). The results…
View more